A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT07038369 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Breast Cancer
Breast Carcinoma
Breast Neoplasms
ER Positive Breast Cancer
Cervical Cancers
Cervical Neoplasms
Cervical Carcinoma
Triple Negative Breast Cancer
Gynecologic Cancers
Gynecologic Neoplasm
Endometrial Cancer
Endometrial Neoplasm
Endometrial Carcinoma (EC)
Fallopian Cancer
Ovarian Carcinoma
Ovarian Cancer
Ovarian Neoplasms
Prostate Cancers
Prostate Carcinoma
Solid Tumors
Neoplasms
Neoplasms by Site
Breast Diseases
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms

Interventions

DRUG: ATV-1601
COMBINATION_PRODUCT: ATV-1601 + Fulvestrant

Sponsor

Atavistik Bio, Inc